Peptide Receptor Radionuclide Therapy (PRRT) Market Key Players Report 2018 and Future Opportunity Assessment 2030

Global Peptide Receptor Radionuclide Therapy (PRRT) Market: Overview

Peptide receptor radionuclide therapy (PRRT) is a molecular therapy which is also called radioisotope therapy. This type of therapy is used to treat a specific type of cancer called neuroendocrine tumors.
In peptide receptor radionuclide therapy, a targeting protein or peptide is combined with a small amount of radioactive material and injected into the patients’ bloodstream. This radiopeptide travels to and binds to neuroendocrine tumor cells, delivering a targeted high dose of radiation directly to the cancer cells.
The global peptide receptor radionuclide therapy (PRRT) market is projected to expand at a significant pace during the forecast period, owing to increase in incidence of mainly gastro-entero-pancreatic

Key Drivers of Global Peptide Receptor Radionuclide Therapy (PRRT) Market

Rise in awareness about effective use of peptide receptor radionuclide therapy is one of the important factors, which is likely to drive the market. Peptide receptor radionuclide therapy offers more personalized cancer treatment because radiopeptides are highly selective in their ability to specifically reach and damage neuroendocrine tumor cells, while limiting the radiation exposure. This has increased the global demand for usage as therapy in treating neuroendocrine cancers.
Moreover, favorable reimbursement is likely to drive the market. Standard therapy with 177Lu-DOTATATE is approved by the FDA in the U.S. and by the EMA in the European Union.

Restraints of Global Peptide Receptor Radionuclide Therapy (PRRT) Market

Supply of radioisotopes is unstable globally and is expected to reduce in the near future due to shut down of major reactors (Canada and the Netherlands)
Short half-life radioisotopes cannot be supplied to other regions where the production of raw materials is negligible, as these disintegrate rapidly
Moreover, several patients may experience nausea and vomiting after the administration of the peptide receptor radionuclide therapy. This is managed with anti-nausea medication or slowing down the administration of the amino acids. Long-term side effects can include a suppression of blood cell counts, which is mild to moderate in the majority of cases associated with the therapy. This is expected to hamper the growth of the market.

North America to Account for Major Share of Global Peptide Receptor Radionuclide Therapy (PRRT) Market

Increase in access to health care, rise in incidence of cancer patients, and rapid introduction of advanced therapy and favourable reimbursement are some factors that likely to drive the market in North America
Asia Pacific is expected to grow at significant rate, owing to growing demand for advancement treatment options and comparatively high prevalence of cancer in countries such as India, Taiwan, and China